Ascendis Pharma

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes on its TransCon technologies to create prodrugs that provide for the predictable and sustained release of an unmodified parent drug. The company was founded by Jan Moller Mikkelsen, Dirk Vetter, and Harald Rau in September 2006 and is headquartered in Hellerup, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ascendis Pharma reports strong revenue growth and market potential

Ascendis Pharma's financial performance in Q4 2022 showed revenue growth but operating losses, with a strong cash position.
Strengths lie in the TransCon technology platform, differentiation of products, and established commercial infrastructure.
Challenges include monitoring requirements, launch strategy comparisons, and market access strategies.
Opportunities arise from potential approvals, market dynamics, and clinical benefits of product candidates.

Ascendis Pharma reports robust Q1 revenue, faces regulatory challenges

Ascendis Pharma delivered a strong financial performance in Q1 2023, driven by revenue growth and strategic initiatives.
The company faces regulatory challenges and market dynamics that require resolution and strategic planning for sustained growth.
Opportunities for market expansion and product development exist through leveraging success factors and addressing regulatory hurdles.
Investor interest in Ascendis Pharma's future prospects is evident through analyst inquiries on growth expectations and market strategies.

Ascendis Pharma reports robust Q2 earnings amidst market challenges

Ascendis Pharma's Q2 performance reflects strong revenue generation and strategic advancements in key product pipelines, positioning the company for future growth.
Despite challenges in market shortages and regulatory processes, Ascendis Pharma's focus on innovation and market differentiation presents opportunities for expansion.
The company's emphasis on TransCon technology's unique benefits and market positioning underscores its competitive strength and growth potential in rare disease therapeutics.

Ascendis Pharma reports strong Q3 revenue growth and pipeline progress

Ascendis Pharma's Q3 2023 performance reflects revenue growth driven by SKYTROFA and progress in key pipeline programs.
The company's strategic focus on innovative therapies and patient-centric approaches positions it for future growth and market leadership.
While facing challenges like supply chain disruptions and market competition, Ascendis Pharma has opportunities for expansion and therapeutic innovation.
Balancing financial performance with pipeline advancement and commercial optimization will be crucial for Ascendis Pharma's sustainable success.

Ascendis Pharma excels in revenue growth and market leadership

Ascendis Pharma's strong performance in 2023, driven by SKYTROFA and TransCon PTH, positions the company for continued growth and success.
Despite challenges in market competition and treatment complexities, the company's strategic focus on patient outcomes and revenue growth is evident.
Opportunities in expanding therapeutic areas and maintaining market share stability offer potential for Ascendis Pharma's long-term success and value creation.

Ascendis Pharma reports robust Q1 performance and eyes global expansion

Ascendis Pharma's Q1 2024 performance reflects strong revenue growth, improved operational efficiency, and successful product launches, positioning the company for sustainable growth.
While facing challenges in market competition and financial targets, Ascendis Pharma's strategic strengths in product development and market expansion present growth opportunities.
The company's focus on innovation, commercial execution, and market positioning underscores its potential to become a leader in growth disorders and metabolic diseases.
Investors should monitor Ascendis Pharma's progress in achieving cash flow breakeven, expanding product portfolios, and navigating regulatory landscapes for future growth potential.

Ascendis Pharma excels in Q2 with YORVIPATH approval and revenue growth

Ascendis Pharma's Q2 2024 earnings call highlighted strong financial performance, successful product approvals, and strategic commercialization efforts.
The company faces challenges in pricing strategies, market dynamics, and ensuring patient uptake, but opportunities exist in expanding market reach and advancing pipeline programs.
Overall, Ascendis Pharma's focus on innovation, patient support, and financial growth positions it well for continued success and market leadership in the biopharmaceutical industry.

Ascendis Pharma reports robust Q3 performance and eyes strategic growth

Ascendis Pharma showcased strong performance across its product portfolio and pipeline candidates, with notable revenue growth and promising clinical outcomes.
While facing challenges in market penetration and regulatory processes, the company is well-positioned to capitalize on growth opportunities through strategic collaborations and upcoming product launches.
By navigating challenges effectively and leveraging opportunities, Ascendis Pharma aims to drive sustainable growth and value creation in the pharmaceutical market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

–   On track to fulfill all elements of Vision 3x3 to build a sustainable, profitable, leading biopharma company

Ascendis Pharma Provides Update on Vision 3x3 Strategic Roadmap at 41st Annual J.P. Morgan Healthcare Conference

-  The program will allow physicians to request access to TransCon PTH, the company's investigational parathyroid hormone replacement therapy, for eligible patients in the United States

Ascendis Pharma to Initiate TransCon™ PTH U.S. Expanded Access Program for Adult Patients with Hypoparathyroidism

COPENHAGEN, Denmark, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) announced today that the company is scheduled to participate in the 5th Annual Evercore ISI HealthCONx Conference. Company executives will participate in a virtual fireside chat hosted by Evercore.

Ascendis Pharma to Participate in the 5th Annual Evercore ISI HealthCONx Conference

TransCon PTH is designed to be the first parathyroid hormone replacement therapy, addressing an area of major unmet medical need TransCon PTH is designed to be the first parathyroid hormone replacement therapy, addressing an area of major unmet medical need

Ascendis Pharma Submits Marketing Authorisation Application to the European Medicines Agency for TransCon™ PTH in Adult Patients with Hypoparathyroidism

-   Data demonstrated that once-weekly TransCon CNP has the potential to meet patient and caregiver needs for a safe, effective, tolerable and convenient treatment

Once-Weekly TransCon™ CNP Achieved Primary Efficacy Objective, with Superiority at 100 µg/kg/week, in Ascendis Pharma's Phase 2 ACcomplisH Trial of Children with Achondroplasia Aged 2 to 10 Years

- Early signs of clinical activity were observed in patients receiving TransCon TLR7/8 Agonist as monotherapy or in combination with pembrolizumab; abscopal effect observed with monotherapy

Dose Escalation Data from transcendIT-101, Ascendis Pharma's Phase 1/2 Trial of TransCon™ TLR7/8 Agonist in Patients with Advanced Solid Tumors, Presented at SITC 2022

Ascendis Pharma A/S (ASND) Q3 2022 Earnings Conference Call November 2, 2022 4:30 PM ET Company Participants Tim Lee - Senior Director, Investor Relations Jan Mikkelsen - President & Chief Executive Officer Scott Smith - Senior Vice President & Chief Financial Officer Stina Singel - Head of Clinical Development Oncology Birgitte Volck - Senior Vice President Head of Clinical Development & Medical Affairs Endocrinology Rare Diseases Joe Kelly - Head of US Commercial Endocrinology Conference Call Participants Jess Fye - JPMorgan Josh Schimmer - Evercore ISI David Lebowitz - Citibank Li Watsek - Cantor Paul Choi - Goldman Sachs Vikram Purohit - Morgan Stanley Leland Gershell - Oppenheimer Joseph Schwartz - SVB Securities Andreas Argyrides - Wedbush Securities Yaron Werber - Cowen Operator Good day, and thank you for standing by. Welcome to the Ascendis Pharma Third Quarter Earnings Conference Call.

Ascendis Pharma A/S (ASND) Q3 2022 Earnings Call Transcript

Ascendis Pharma has one commercial product and another with a PDUFA date in early 2023 and a path to profitability. The validated platform has produced best in class medicines and in Q4 there will be multiple data readouts which could further de-risk the company.

Ascendis Pharma: Translating Valuable IP Into A Profitable Business

- SKYTROFA ® U.S. revenue more than doubled quarter-to-quarter again, reaching €12.3 million in the third quarter

Ascendis Pharma Reports Third Quarter 2022 Financial Results

- PDUFA target action date is April 30, 2023

FDA Accepts for Priority Review Ascendis Pharma's NDA for TransCon™ PTH in Adult Patients with Hypoparathyroidism

The consensus price target hints at a 34.6% upside potential for Ascendis Pharma AS (ASND). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Does Ascendis Pharma AS (ASND) Have the Potential to Rally 35% as Wall Street Analysts Expect?

MENLO PARK, Calif.--(BUSINESS WIRE)--Frazier Life Sciences announced the addition of Jan Møller Mikkelsen as a Senior Advisor. He has over 30 years of experience as a biopharmaceutical executive. Mr. Mikkelsen founded Ascendis Pharma (NASDAQ: ASND) and currently serves as full-time President and Chief Executive Officer, as well as a board member. He previously served as President and Chief Executive Officer of LifeCycle Pharma A/S (acquired by Asahi Kasei Pharma), as well as President of the Ph

Frazier Life Sciences Adds Experienced Biopharmaceutical Executive to Team

- TransCon TLR7/8 Agonist continued to be well-tolerated and demonstrated early signs of clinical activity as monotherapy or in combination with pembrolizumab

Ascendis Pharma Announces Recommended Phase 2 Dose and Cohort Expansion for transcendIT-101, a Phase 1/2 Clinical Trial of TransCon™ TLR7/8 Agonist in Solid Tumors

Ascendis Pharma is now a commercial-stage company with a full pipeline and a revenue stream. There are multiple upcoming catalysts, including oncology data due by year end, which may validate the breadth of the platform.

Ascendis Pharma: TransCon CNP Data Coming Q4

•   TransCon PTH could , if approved, become the first hormone replacement therapy to address the underlying cause of hypoparathyroidism, an area of major unmet medical need for the estimated 70,000-90,000 adults living with chronic disease in the United States alone.

Ascendis Pharma Submits TransCon™ PTH New Drug Application to the U.S. FDA for Adult Patients with Hypoparathyroidism

Ascendis Pharma A/S (ASND) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants Tim Lee - Senior Director, Investor Relations Jan Mikkelsen - President and Chief Executive Officer Scott Smith - Senior Vice President and Chief Financial Officer Dana Pizzuti - Head, Development Operations and Chief Medical Officer Stina Singel - Head, Clinical Development Oncology Joe Kelly - Head, U.S. Commercial Endocrinology Conference Call Participants Jessica Fye - JPMorgan Josh Schimmer - Evercore Tazeen Ahmad - Bank of America David Lebowitz - Citibank Li Watsek - Cantor Vikram Purohit - Morgan Stanley Operator Good day and thank you for standing by. Welcome to the Ascendis Pharma Second Quarter 2022 Earnings Conference Call.

Ascendis Pharma A/S (ASND) CEO Jan Mikkelsen on Q2 2022 Results - Earnings Call Transcript

—  U.S. regulatory submission for TransCon PTH, designed to be the first parathyroid hormone replacement therapy, on track for Q3 2022; EU submission planned for Q4 2022

Ascendis Pharma A/S Reports Second Quarter 2022 Financial Results

COPENHAGEN, Denmark, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) announced today that the company will hold a conference call and live webcast on Wednesday, August 10, 2022, at 4:30 p.m. Eastern Time (ET) to review its second quarter 2022 financial results and provide a business update.

Ascendis Pharma A/S Announces Second Quarter 2022 Financial Results and Business Update Conference Call on August 10

Investors are reacting negatively to the company's Q1 update.

Why Ascendis Pharma Stock Is Sinking Today

Ascendis Pharma A/S (ASND) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Jan Mikkelsen – President and Chief Executive Officer Scott T. Smith – Senior Vice President and Chief Financial Officer Timothy J.

Ascendis Pharma A/S (ASND) CEO Jan Mikkelsen on Q1 2022 Results - Earnings Call Transcript

COPENHAGEN, Denmark, May 11, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the first quarter ended March 31, 2022 and provided a business update.

Ascendis Pharma A/S Reports First Quarter 2022 Financial Results

Ascendis Pharma (ASND) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Ascendis Pharma (ASND) Might Surprise This Earnings Season

COPENHAGEN, Denmark, May 09, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) announced today that the company is scheduled to attend the BofA Securities 2022 Healthcare Conference. Company executives will participate in a fireside chat hosted by BofA on Thursday, May 12.

Ascendis Pharma A/S to Participate in the BofA Securities 2022 Healthcare Conference

Shares have lost nearly 40% of their value year to date. I provide a recap of the bullish thesis, which has strengthened considerably with conclusive phase 3 data for TransCon PTH.

News for Ascendis Pharma Stock (ASND)